CagriSema is a subcutaneous injectable combination of cagrilintide and semaglutide that is currently in phase 3 trials.
Vidhi Patel, PharmD Candidate
Advertisement
Articles by Vidhi Patel, PharmD Candidate
Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.
Thiazolidinediones may change metabolic patterns and contribute to weight gain.
Advertisement
Latest Updated Articles
An Overlook of Cagrilintinide and Semaglutide as it Progresses Through Phase 3 TrialsPublished: November 11th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
CDC Adolescents, Children, & Adult Immunization Schedule: 2025 Update
2
Regular Melatonin Supplementation May Hide Hidden Heart Complications
3
Lower LDL-C Correlated With Lower Risk of MACE in Ischemic Stroke Survivors
4
How Rapid RSV Testing Shapes Clinical Decisions and Patient Outcomes
5
